BMS-986497 (ORM-6151)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BMS-986497 (ORM-6151), covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]